Imagine a digital breathalyzer that can tell if your liver is unhealthy just by how you breathe. Instead of painful needle biopsies or expensive scans, this device smells a unique chemical fingerprint in your breath. It uses AI to spot patterns that signal liver disease long before symptoms appear.
Liver disease diagnosis currently relies on invasive biopsies or expensive, inaccurate scans. This leads to late-stage diagnosis for a condition affecting 40% of the global population.
An alpha prototype of the DiaNose handheld device was built, with an advanced beta prototype currently under development for clinical validation.
If you are a clinic dealing with the rising epidemic of fatty liver disease — this project developed a handheld sensor that provides screening at <50€ per test. This allows for early detection in primary care without needing expensive imaging or invasive biopsies.
If you are a manufacturer dealing with the lack of accurate, non-invasive liver screening tools — this project developed a beta prototype using cross-reactive nano sensors. It aims for a diagnostic accuracy of >90% to replace operator-dependent methods.
If you are a health authority dealing with MASLD generating over €35 billion in direct healthcare costs annually — this project developed a point-of-care device to reduce undiagnosed cases. Early detection helps lower the long-term economic burden of liver failure and cancer.
The project aims to achieve a diagnostic cost of less than 50€ per test.
The project is moving from an alpha prototype to an advanced beta prototype for clinical validation, indicating it is in the pre-commercial scaling phase.
The device utilizes an array of patented cross-reactive sensors to deliver chemical signatures of breath.
Unlike liver biopsies which are invasive and expensive, this device is portable, fast, and non-invasive.
Lab testing of the alpha prototype showed 88% accuracy, with the project aiming for >90% accuracy in the beta version.
The project is led by a single SME, NaNose Medical Ltd from Israel, which holds 100% of the industry ratio. This lean structure suggests a fast-track transition from research to commercialization, as the coordinator is the sole entity managing the development of the beta prototype.
Contact NaNose Medical Ltd regarding the DiaNose beta prototype clinical validation.
Contact us to explore licensing opportunities for nano-sensor breath diagnostics.
